ABSTRACT
INTRODUCTION
Tau aggregation is the prominent signature of Alzheimer and other diseases termed tauopathies (1) (2) (3) It is linked to neuronal death and sufficient to induce neurodegeneration (2, 4) . In Alzheimer, aggregation of Tau into fibrils correlates with cognitive impairment in humans (5) . Understanding Tau biology is thus of paramount importance to understand neurodegeneration.
Tau protein is predominantly expressed in the central nervous system, with six documented isoforms obtained from alternative splicing and developmentally regulated (4) . Tau belongs to the family of microtubule associated proteins, or MAPs, collectively orchestrating microtubule assembly (6) , This family of proteins act redundantly, as Tau null mice show no phenotype and have increased levels of the paralog MAP1A (7) . Studies attempting to propose a role of Tau in axon growth yielded varying results, based on the cell lines investigated (7, 8) . Recent data demonstrated how Tau and other MAPs compete to distribute cargos correctly ( (9)). Thus, Tau is bound to microtubules in physiological state, and its detachment from them is a necessary step preceding aggregation and pathology.
Tau binding to microtubules is highly dynamic and regulated by phosphorylation, with Tau having more than 40 potential phosphorylation sites (10) . Phosphorylation and consequent detachment from microtubule are thought to be the initial steps triggering Tau aggregation in dementia, however recent structural data show that phospho-sites do not have a structural role in the assembly of Tau aggregates (11, 12) . Also, hyperphosphorylation is fundamental for hibernation of rodents but does not lead to dementia (6) . Finally, some phosphorylation sites may have a protective role against Tau aggregation (13) . Thus, Tau hyperphosphorylation cannot explain alone aggregation and disease progression.
Tau aggregation may be caused by the collapse of the chaperone network instead (14) . Tau sequence itself endows the potential for Tau aggregation. Tau is a disordered protein of 441 residues in its longest isoform (4, 15) . Tau Nterminus composition enhance its solubility, with few hydrophobic residues (10.6 non hydrophobic residues per hydrophobic one (16) ). On the contrary, microtubule binding region has higher hydrophobic content (4.4 non hydrophobic residues per hydrophobic one), and indeed is the region comprising the core of amyloid structures of Alzheimer's and Pick's Disease (11, 12) . Although Tau is soluble and dynamic, its own sequence has the potential to convert to toxic folds. Surprisingly, it is hard to pinpoint the (18, 19) .
Here, we present an alternative protocol to obtain recombinant Tau from Escherichia coli. Compared to previous protocol, we introduced a cleavable tag His 6 -Smt at the Nterminus to maintain a tag-less version of the protein. We introduced a second anion exchange purification step to remove the tag and to further decrease impurities. Despite this extra purification step, the resulting protocol was still fast, meaning that Tau purification -from cell lysate to pure protein -takes 1 to 2 days, based on the purified variant. We show that the protocol robustly purified also a FLAG-tagged version of Tau at the N-terminus. This variant can be used for instance to perform pull-down experiments or to favour Tau detection with an antibody.
We obtained Tau preparations of high purity and yields (between 1 and 3 mg of proteins per 1 l of bacterial culture), suitable for aggregation experiments and other applications.
RESULTS

Design of biologically relevant Tau variants
The Tau protein consists of several functionally relevant regions (Fig.  1A) . The N-terminal region (A2-L243) is important for Tau sorting in the cell and is endowed with a proline-rich domain, whose isomerization is possibly linked to increased aggregation propensity (20) . After this stretch, the repeat domains follow (Q244-N368), which consists of fourpseudo-repeats. They are responsible for binding to microtubules and participating to the formation of amyloid structures, in particular the 3 rd and 4 th repeats (11, 12) . The C-terminal region (K369-L441) is physiologically removed when Tau is secreted in the cerebrospinal fluid (21 (19) . To this end, we generated a truncation of Tau comprising the four repeats (Tau-Q244-E372; Tau Repeat Domain, Tau-RD, also referred to as K18 in the literature ( (23)), with reported faster aggregation rates, in the time scale of hours (24) . This truncation is an established disease model, causing neurodegeneration in mice (25) . 
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5 All of our constructs were designed with a cleavable His 6 -Smt tag at the N-terminus. A hexahistidine tag serves as a purification tag, while Smt is a globular domain that favours protein production. After cleavage, Tau protein comprises all residues between A2 and L441 (Fig.  1B) . Regarding Tau-RD, we added a FLAG tag (DYKDDDDK) at the Nterminus, immediately C-terminal of the cleavage site of Smt1, composed of two Glycines (GG). Thus, the tag is retained after cleavage. It serves for downstream applications, such as western blot detection or pull-down experiments, and positioning at the N-terminus avoids interference with the aggregating regions present toward the C-terminus. Taken together, our designed constructs are suitable to study Tau phosphorylation, aggregation and other aspects of Tau biology.
Tau sequence properties define strategies for purification
When analysing the amino acidic distribution in Tau, we noted asymmetry in the distribution of charges (Fig. 1B) . We calculated the isoelectric point (pI) of various segments of Tau based on their composition. While the N-and Cterminal regions (A2-L243 and K369-L441) have a pI of 5.7 and 7.0 respectively, the repeat domain has a pI of 9.7. This implies that at the physiological pH of the cell the Nterminal region is negatively charged, while the repeat domain is positively charged, and the Cterminal region has a near-neutral net charge. Of note, the His 6 -Smt tag has a pI of 5.3, being thus negatively charged at physiological pH. These differentially charged domains can be exploited for binding to different ion exchanges columns, to achieve greater purity of the sample.
Production and Purification of full-length Tau
First, we aimed to develop a strategy to purify full-length Tau ( Fig. 2A) . First, E. coli BL21 DE3 Rosetta 2 cells were transformed with a plasmid encoding for a Tau variant. We chose this cellular strain as it encodes a T7 polymerase necessary to transcribe Tau plasmid. It also encodes for suppressor tRNAs for rare codons, which appear frequently in the human Tau construct. Cells were then induced with Isopropyl β -D-1-thiogalactopyranoside (IPTG) at an optical density (OD) at 600 nm of 0.8, and they were cultured over night at 18°C. Next, they were lysed. Subsequently we heated the lysate at 95°C. This is a key step to increase sample stability as Tau is an intrinsically disordered protein (IDP). Tau cannot, therefore, lose potentially folded structure. The majority of proteins, including proteases, became insoluble and precipitated under these conditions, whereas Tau remained in the supernatant due to its high solubility and lack of folded domains, which could become potentially
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BioRxiv Preprint 6 aggregation-prone after unfolding. Tau-containing supernatant was loaded on an affinity purification column, to which it bound thanks to the His 6 tag at the N-terminus of the protein. After elution by an imidazole gradient, the protein was further purified with an anion exchange column. Tau was then eluted in a salt gradient. We pooled the Tau 
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containing fractions and cleaved off the His 6 -Smt by adding Ulp1 hydrolase to obtain an untagged Tau species. The resulting protein mix was then loaded on a cation exchange column, where effective separation of Tau from the tag took place upon elution with a salt gradient, due to the different net charges of Tau (positively charged 
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8 Tau-RD allowed binding to the column) and His 6 -Smt (negatively charged, repelled by the column and found in flow through). This was a critical step to achieve high purity, as differences in the equilibration pH of the cation column yielded less pure eluates, possibly favouring the binding of differentially charged Tau truncation and/or impurities (Fig.  2B) . While an eluting pH of 7.5 resulted in pure protein, pH of 3. 0, 5.5 and 6.5 yielded less pure protein.
We monitored the purification scheme and sample quality by SDS-PAGE (Fig. 2C) , highlighting the high degree of purity of the final product. We obtained between 5 and 10 mg of proteins per 3.2 l of bacterial culture (n=3).
Robust purification of Tau variants
Next we set out to adapt our protocol for purifying Tau-RD. Remarkably, we could not retrieve protein after heating. We concluded that the highly charged terminal regions increased overall solubility, in line with the observation that Tau-RD is more prone to form fibrils than the full length protein. We consequently adapted the protocol by removing the boiling step (Fig.  3A) . As Tau-RD has a net positive charge at physiological pH, we also avoided the anion exchange purification step. To compensate for lacking these two steps, we added a size exclusion chromatography step downstream of the purification scheme to remove eventual high molecular weight contaminants. Our adapted protocol resulted in highpurity Tau-RD, as assessed by SDS-PAGE (Fig. 3B) . We obtained between 4.0 and 8.7 mg of proteins per 3.2 l of bacterial culture (n=5).
Importantly, the two protocols presented for full-length Tau and Tau-RD were extended to other Tau variants, containing for instancepseudo-phosphorylated residues or FLAG-tag, nonetheless yielding pure proteins (Fig. 3C) . In the case of FLAG-tagged constructs, His 6 -Smt cleavage was extended overnight, as a one-hour treatment was not sufficient to cleave the protein completely. Thus, we could further adapt our protocol developed for full-length Tau to other Tau variants.
Purified
Tau aggregates successfully
We tested the quality of our purified proteins by employing them in an established aggregation assay (26) . The negatively charged polymer initiates Tau fibrillation, which is a reliable and reproducible method to study kinetics of Tau aggregation and other aspects linked to Tauinduced neurodegeneration. First, we monitored via SDS-PAGE the aggregation propensity over time of full-length Tau in the presence of increased amounts of heparin (Fig.  4A) . We observed the appearance of SDS-insoluble aggregates after 6 days of aggregation, at the optimal stoichiometry of four molecules of Tau per molecule of heparin. This is an established stoichiometry to
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obtain Tau aggregates resembling Alzheimer's Paired Helical Filaments (27) . We did not observe formation of aggregates at sub-stoichiometric Tau:heparin ratios during the time frame of our experiments, whereas excess of heparin interfered with Tau running on the electrophoresis gel, probably due to the high number of negative charges decorating heparin. Thus, our experiment confirmed that our Tau preparation have similar aggregation properties as Tau batches purified with other protocols (18, 19) . Compared to other protocols, our purification setup allows purifying Tau variants with different biochemical properties, such as increased aggregation propensity, pseudo-phosphorylated sites or a FLAG-tag at their Nterminus. This versatility does not come at the expense of yields, 
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10 purity and purification time. Tau preparations were stable even after a week of incubation at 37°C, proving that our purification procedure is highly effective in removing contaminant proteases (Fig. 4A) .
We further tested the robustness of our protocol by inducing aggregation of Tau-RD domain. We used the Thioflavin T assay to monitor kinetics of aggregation over time. This is an established technique to study aggregation dynamics, in which a fluorescent dye binds to fibrils but not monomers of Tau, resulting in a fluorescent signal allowing monitoring aggregation over time (28) . We kept the Tau:heparin ratio as 4:1, this time changing the concentration of monomeric Tau-RD at the beginning of the aggregation, to test (Fig. 4B) .
Increased concentrations of Tau accelerated
Tau aggregation, consistent with the proposed model of nucleation-elongation proposed for heparin-induced Tau aggregation (29) . Thus, our protocol yields Tau variants whose aggregation dynamics are in agreement with published material.
DISCUSSION
Here, we presented a protocol to purify Tau species after recombinant production in Escherichia coli. Purification of intrinsically disordered proteins is challenging and may require tedious optimization (30) . Our protocol allows Tau purification with standard purification equipment and buffers. Compared to previous Tau purification methods, our protocol allows to purify Tau either tag-less or with a tag of choice, thanks to the removable His 6 -Smt tag at the Nterminus of the protein (18, 19) . Tau distribution of charges allows effective purification and removal of the His 6 -Smt. Indeed, Tau can both bind to an anion and cation exchange column, the latter used to effectively separate the tag from the purified protein. Most of bacterial proteome has a distribution of isoelectric points lower than 7, thus is negatively charged at physiological pH and removed either by the Nickel column or by the cation exchange column (31) . A sub-fraction of the proteome, mostly DNA and RNA binding proteins, is positively charged and thus effectively removed by the anion exchange column. Overall, a double ion-exchange column approach allows effective purification of Tau protein.
Interestingly, the elution buffer of the cation exchange column greatly influences the purity of Tau fulllength (Fig. 2B) . This is probably due to the asymmetric distribution of charges throughout the random coils of Tau protein, exposing different charged patches that bind to the column as pH changes. This distribution is also important for physiological functions of Tau, as the high pI of Tau-RD is necessary for binding to microtubules. In contrast, the N terminal regions of Tau are negatively charged, similar
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11 to most cytoplasmic proteins, such that they remain dynamic and exposed even when bound to microtubules (4).
We could not apply the same exact protocol to Tau-RD truncations, as they lack the N-terminus region necessary to bind to the anion exchange column. Tau-RD could not be retrieved after the boiling step, suggesting that the N-and Ctermal regions drastically increase Tau solubility. Of note, a study presenting a general purification protocol for disordered proteins based on boiling cell lysates suggests that Tau-RD behaves atypically compared to other disordered segments (32) . These differences in solubility may also have had an influence on the evolution of physiologically relevant Tau truncations. Indeed, Tau truncations at the N-terminus are found in humans in physiological conditions, whereas C-terminal truncations were not detected (21) . It is tempting to speculate that their higher propensity to aggregate negatively selected them, in favour of more soluble N-terminal truncations.
Our designed Tau constructs, both full-length and RD, aggregate with an optimal Tau:heparin stoichiometry of 4:1, in agreement with published protocols, suggesting that our Tau constructs can be used to model aggregation in Alzheimer and other forms of dementia (28, 29) . Indeed, we used N-terminally FLAG-tagged Tau-RD to create Alzheimer-like fibrils, which we could later disaggregate with the human Hsc70 chaperone system (33) . To conclude, we present a protocol yielding pure and stable Tau constructs suitable for a wide array of in vitro studies.
ACKNOWLEDGMENTS
We are grateful to Ineke Braakman for continuous support. 
COMPETING INTERESTS
The authors declare no competing interests.
MATERIALS AND METHODS
Isoelectric points calculation
Theoretical isoelectric points were calculated using ProtParam tool (https://web.expasy.org/protparam/).
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Purification of Tau variants
We designed two types of Tau constructs, full-length and Repeat Domain (Fig. 1A) . We propose two purification protocols, based on the variants to be purified.
Purification of human full-length Tau
Following, a step-by step procedure to purify human full-length Tau: 
Purification of human Tau-RD
Following, a step-by step procedure to purify human Tau-RD: 
Formation of Tau fibrils
Monomeric human full-length Tau was aggregated by adapting a published procedure (34 
ThioflavinT assay
N-terminally FLAG-tagged Tau-RD (100 µl) of varying concentrations , 60 μM ThioflavinT (Sigma) and 5μM heparin Low Molecular Weight were aggregated in aggregation buffer in a transparent, lidded Greiner 96-well plate (Sigma-Aldrich). Fluorescent spectra were recorded with a SpectraMax i3 (Molecular Devices) every 10 minutes for 16 hours.
